Utility of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as biomarker to predict therapeutic response to methotrexate in rheumatoid arthritis. Issue 7 (October 2017)

• Record Type: Journal Article
• Authors: Gamez-Nava, Jorge I.; Bonilla-Lara, David; Ponce-Guarneros, Juan M.; Zuñiga-Mora, J. Alejandro; Perez-Guerrero, Edsaul E.; Murillo-Vazquez, Jessica D.; Becerra-Alvarado, Itzel N.; Rodriguez-Jimenez, N. Alejandra; Saldaña-Cruz, A. Miriam; Vazquez-Villegas, M. Luisa; Vera-Navarrete, Erika Y.; Gonzalez-Ponce, Fabiola; Gonzalez-Lopez, Laura
• Is Part Of: Innate immunity. Volume 23:Issue 7(2017:Oct.)
• Page Start: 606
• Page End: 614
• Publication Date: 2017-10
• Subjects: Biomarker -- methotrexate -- rheumatoid arthritis -- sTREM-1 -- therapeutic response; Natural immunity -- Periodicals; Endotoxins -- Periodicals; 616.07905
• DOI: 10.1177/1753425917726862
• Languages: English
• ISSNs: 1753-4259

Abstract

The objective of this study was to investigate the usefulness of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in predicting short-term therapeutic response to methotrexate (MTX) in rheumatoid arthritis (RA). Patients with active RA, with Disease Activity Score-28 joints (DAS-28) >3.2, starting oral MTX, were included. We measured at baseline, 3 and 6 mo: DAS-28, Health Assessment Questionnaire–Disability Index (HAQ-DI), patient's perception of disease severity, morning stiffness and pain, as well as modifications in sTREM-1 levels. A reduction in DAS-28 > 1.2 at 3 or 6 mo was considered adequate response. A significant decrease in DAS-28 was observed at 3 and 6 mo. HAQ-DI also decreased at 3 and 6 mo. No significant changes were observed in sTREM-1 levels at 3 or 6 mo. Using as cut-off a baseline value of sTREM-1 levels > 390 pg/ml, we obtained low values of sensitivity (61.5%), specificity (59.3%), positive predictive value (59.3%) and negative predictive value (61.5%) for adequate response to MTX at 3 mo. We found no clinical value of sTREM-1 levels in predicting therapeutic response to MTX in RA. Further studies should evaluate if sTREM-1 levels are predictive for other outcomes, including higher structural damage or good response to biologics.